This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Cellid Co: AdCLD-CoV19

Cellid Co: AdCLD-CoV19

Vaccine Type: Replicating Viral Vector

About Trial Phases

Phase 1: 2 Trials

NCT04666012
Republic of Korea
NCT05576623
Republic of Korea

Phase 2: 3 Trials

NCT04666012
Republic of Korea
NCT05520970
NCT05576623
Republic of Korea

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

NCT05520970
Phase 2
Total Enrollment: 200
Official Trial Registration:
- NCT05520970(Opens in new tab/window)
NCT04666012
Phase 1/2
Republic of Korea
Total Enrollment: 150
Official Trial Registration:
- NCT04666012(Opens in new tab/window)
NCT05576623
Phase 1/2
Republic of Korea
Total Enrollment: 320
Official Trial Registration:
- NCT05576623(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form